CLOS
VKTX icon

Compagnie Lombard Odier SCmA’s Viking Therapeutics VKTX Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Hold
30,245
– – 0.01% 167
2026
Q1 		$984K Buy
30,245
+14,000
+86% +$450K 0.01% 159
2025
Q4 		$571K Sell
16,245
-4,000
-20% -$142K 0.01% 192
2025
Q3 		$532K Sell
20,245
-5,000
-20% -$149K 0.01% 190
2025
Q2 		$669K Buy
25,245
+5,000
+25% +$132K 0.01% 170
2025
Q1 		$489K Buy
20,245
+15,000
+286% +$474K 0.01% 200
2024
Q4 		$211K Buy
5,245
+245
+5% +$14K ﹤0.01% 238
2024
Q3 		$317K Hold
5,000
– – ﹤0.01% 208
2024
Q2 		$265K Hold
5,000
– – ﹤0.01% 218
2024
Q1 		$410K Buy
+5,000
New +$222K 0.01% 202

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Compagnie Lombard Odier SCmA's VKTX Position: Q2 2026 in Review

Compagnie Lombard Odier SCmA held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 30,245 shares worth $1.18M. The position accounts for 0.01% of the portfolio, ranked #167.

Compagnie Lombard Odier SCmA first reported a position in VKTX in Q1 2024 and has held it in 10 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Compagnie Lombard Odier SCmA held 30,245 shares of Viking Therapeutics worth $1.18M as of Q2 2026.
  • Compagnie Lombard Odier SCmA left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up 0.01% of Compagnie Lombard Odier SCmA's portfolio in Q2 2026, its #167 holding.
  • Compagnie Lombard Odier SCmA first reported a position in Viking Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2026, filed 29 Jul 2026.